Hydroxyprogesterone caproate (Hydroxyprogesteroni caproas)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

"Estrogens, gestagens, their homologues and antagonists"

Included in the formulation
  • Oxyprogesterone capro- nate
    solution w / m 
    DALHIMFARM, OJSC     Russia
  • Oxyprogesterone capronate injection for oil
    solution w / m 
    DALHIMFARM, OJSC     Russia
    • АТХ:

    G.03.D.A.03   Hydroxyprogesterone

    Pharmacodynamics:17-hydroxyprogesterone is a synthetic analog of progesterone. It binds to the receptors of progesterone of the target cell, penetrates into the nucleus and stimulates DNA. As a result, the synthesis of ribonucleic acids is enhanced. Accelerates the transition of the mucous membrane of the uterus from the proliferation phase to the phase of secretion. Promotes the successful implantation of a fertilized egg. Reduces contractility of the myometrium and musculature of the fallopian tubes. Promotes the development of the end ducts of the mammary glands.

    Pharmacokinetics:

    After subcutaneous or intramuscular injection, the maximum concentration in the blood plasma is achieved in 2-3 minutes. The duration of the action is 7-14 days.

    Metabolism in the liver by conjugation with sulfuric and glucuronic acid.

    The half-life is 5-10 minutes. Elimination by the kidneys.

    Indications:

    Used for hormonal correction of conditions caused by malnutrition of the yellow body: for the prevention and treatment of menacing and started miscarriage, dysfunctional uterine bleeding, primary and secondary amenorrhea.

    ICD-10

    IV.E20-E35.E28   Dysfunction of the ovaries

    XIV.N80-N98.N91   Absence of menstruation, meager and rare menstruation

    XIV.N80-N98.N93   Other abnormal bleeding from the uterus and vagina

    XV.O20-O29.O20.0   Threatening abortion

    XIV.N80-N98.N91.0   Primary amenorrhea

    XIV.N80-N98.N91.1   Secondary amenorrhea

    XIV.N80-N98.N94.6   Dysmenorrhea, unspecified

    Contraindications:

    Hepatic insufficiency, thrombophilia, breast and genital cancers, individual intolerance, children and the elderly.

    Carefully:

    Arterial hypertension, chronic renal failure, epilepsy, bronchial asthma, migraine, ectopic pregnancy, hyperlipoproteinemia, lactation period, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    When treating the threat of termination of pregnancy: intramuscularly for 1-2 ml of 12.5% ​​solution (0.125-0.25 g) once a week.

    With amenorrhea: by 1 ml intramuscularly once, immediately after the completion of estrogen therapy.

    The highest daily dose: 0.25 g.

    The highest single dose: 0.25 g.

    Side effects:

    Central and peripheral nervous system: headache, depression, dysphoria, drowsiness.

    The cardiovascular system: arterial hypertension, thrombophlebitis, thromboembolism, edema, retinal vein thrombosis.

    Digestive system: anorexia, nausea, vomiting, cholestatic hepatitis, rarely - calculous cholecystitis.

    Dermatological reactions: hirsutism, alopecia.

    Sense organs: impaired vision.

    Reproductive system: intermediate bleeding, reduction of the menstrual cycle, decreased libido, mastodynia, mastalgia.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Affects the effectiveness of anticoagulants and hypoglycemic drugs.

    Special instructions:

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    With dysfunctional uterine bleeding appointed for 20-22 day of the cycle in a dose of 1-2 ml once.

    Instructions
    Up